fluorodeoxyglucose f18 has been researched along with buparlisib in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hussien, K; Kelly, CJ; Muschel, RJ | 1 |
| Abramson, VG; Arteaga, CL; Balko, JM; Cantley, LC; Forero, A; Isakoff, SJ; Kuba, MG; Li, Y; Mayer, IA; Sanders, ME; Van den Abbeele, AD; Winer, E; Yap, JT | 1 |
| Bao, X; Lu, S; Niu, X; Wang, M; Wang, Q; Wang, S; Wang, Y; Xu, L; Zhang, J | 1 |
1 trial(s) available for fluorodeoxyglucose f18 and buparlisib
| Article | Year |
|---|---|
Stand up to cancer phase Ib study of pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole in estrogen receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer.
Topics: Adult; Aged; Aminopyridines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorodeoxyglucose F18; Humans; Letrozole; Middle Aged; Morpholines; Multimodal Imaging; Nitriles; Phosphoinositide-3 Kinase Inhibitors; Positron-Emission Tomography; Protein Kinase Inhibitors; Radiopharmaceuticals; Receptor, ErbB-2; Receptors, Estrogen; Tomography, X-Ray Computed; Triazoles | 2014 |
2 other study(ies) available for fluorodeoxyglucose f18 and buparlisib
| Article | Year |
|---|---|
3D tumour spheroids as a model to assess the suitability of [18F]FDG-PET as an early indicator of response to PI3K inhibition.
Topics: Aminopyridines; Animals; Biological Transport; Cell Line, Tumor; Cell Proliferation; Feasibility Studies; Fluorodeoxyglucose F18; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Mice; Morpholines; Phosphoinositide-3 Kinase Inhibitors; Phosphoproteins; Positron-Emission Tomography; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinolines; Spheroids, Cellular; Time Factors; Treatment Outcome | 2012 |
The PI3K inhibitor buparlisib suppresses osteoclast formation and tumour cell growth in bone metastasis of lung cancer, as evidenced by multimodality molecular imaging.
Topics: Aminopyridines; Animals; Antineoplastic Agents; Apoptosis; Bone and Bones; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Molecular Imaging; Morpholines; Osteoclasts; Positron Emission Tomography Computed Tomography; Single Photon Emission Computed Tomography Computed Tomography; Treatment Outcome; X-Ray Microtomography | 2019 |